-
1
-
-
66349100456
-
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
-
Morris MJ, Pandit-Taskar N, Carrasquillo J, et al: Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27:2436-2442, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 2436-2442
-
-
Morris, M.J.1
Pandit-Taskar, N.2
Carrasquillo, J.3
-
2
-
-
66349089867
-
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castrationresistant prostate cancer
-
Fizazi K, Beuzeboc P, Lumbroso J, et al: Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castrationresistant prostate cancer. J Clin Oncol 27:2429-2435, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 2429-2435
-
-
Fizazi, K.1
Beuzeboc, P.2
Lumbroso, J.3
-
3
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
DOI 10.1056/NEJMoa041318
-
Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004 (Pubitemid 39315318)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.A.3
Lara Jr., P.N.4
Jones, J.A.5
Taplin, M.E.6
Burch, P.A.7
Berry, D.8
Moinpour, C.9
Kohli, M.10
Benson, M.C.11
Small, E.J.12
Raghavan, D.13
Crawford, E.D.14
-
4
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
DOI 10.1056/NEJMoa040720
-
Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Theodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
5
-
-
0027252452
-
Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
-
Porter AT, McEwan AJ, Powe JE, et al: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993
-
(1993)
Int J Radiat Oncol Biol Phys
, vol.25
, pp. 805-813
-
-
Porter, A.T.1
McEwan, A.J.2
Powe, J.E.3
-
6
-
-
2342509633
-
Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer
-
DOI 10.1016/j.urology.2004.01.034, PII S0090429504001438
-
Sartor O, Reid RH, Hoskin PJ, et al: Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63:940-945, 2004 (Pubitemid 38596683)
-
(2004)
Urology
, vol.63
, Issue.5
, pp. 940-945
-
-
Sartor, O.1
Reid, R.H.2
Hoskin, P.J.3
Quick, D.P.4
Ell, P.J.5
Coleman, R.E.6
Kotler, J.A.7
Freeman, L.M.8
Olivier, P.9
-
7
-
-
79951895712
-
Market forces cited in lymphoma drugs' disuse
-
July 14
-
Berenson A: market forces cited in lymphoma drugs' disuse. New York Times, July 14, 2007. http://www.nytimes.com/2007/07/14/health/14lymphoma. html
-
(2007)
New York Times
-
-
Berenson, A.1
-
8
-
-
2442699127
-
Cellular interactions in the tropism of prostate cancer to bone
-
DOI 10.1002/ijc.20153
-
Sikes RA, Nicholson BE, Koeneman KS, et al: Cellular interactions in the tropism of prostate cancer to bone. Int J Cancer 110:497-503, 2004 (Pubitemid 38658014)
-
(2004)
International Journal of Cancer
, vol.110
, Issue.4
, pp. 497-503
-
-
Sikes, R.A.1
Nicholson, B.E.2
Koeneman, K.S.3
Edlund, N.M.4
Bissonette, E.A.5
Bradley, M.J.6
Thalmann, G.N.7
Cecchini, M.G.8
Pienta, K.J.9
Chung, L.W.K.10
-
9
-
-
0035798930
-
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial
-
DOI 10.1016/S0140-6736(00)03639-4
-
Tu SM, Millikan RE, Mengistu B, et al: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 357:336-341, 2001 (Pubitemid 32128538)
-
(2001)
Lancet
, vol.357
, Issue.9253
, pp. 336-341
-
-
Tu, S.-M.1
Millikan, R.E.2
Mengistu, B.3
Delpassand, E.S.4
Amato, R.J.5
Pagliaro, L.C.6
Daliani, D.7
Papandreou, C.N.8
Smith, T.L.9
Kim, J.10
Podoloff, D.A.11
Logothetis, C.J.12
-
10
-
-
34347244905
-
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study
-
DOI 10.1016/S1470-2045(07)70147-X, PII S147020450770147X
-
Nilsson S, Franzén L, Parker C, et al: Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebocontrolled phase II study. Lancet Oncol 8:587-594, 2007 (Pubitemid 46995621)
-
(2007)
Lancet Oncology
, vol.8
, Issue.7
, pp. 587-594
-
-
Nilsson, S.1
Franzen, L.2
Parker, C.3
Tyrrell, C.4
Blom, R.5
Tennvall, J.6
Lennernas, B.7
Petersson, U.8
Johannessen, D.C.9
Sokal, M.10
Pigott, K.11
Yachnin, J.12
Garkavij, M.13
Strang, P.14
Harmenberg, J.15
Bolstad, B.16
Bruland, O.S.17
|